BRV 2.5 mg ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
309Progressive myoclonus epilepsy1

309. Progressive myoclonus epilepsy


Clinical trials : 11 Drugs : 15 - (DrugBank : 2) / Drug target genes : 4 - Drug target pathways : 9
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00368251
(ClinicalTrials.gov)
November 200623/8/2006Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseUnverricht-Lundborg DiseaseOther: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mgUCB PharmaNULLCompleted16 YearsN/AAll56Phase 3United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro